HCPCS Code J1950: Leuprolide acetate injection billing guide

Key takeaways

HCPCS Code J1950 covers injection of leuprolide acetate for depot suspension, per 3.75 mg, billed mainly by gynecology, oncology, and pediatric endocrinology practices.

Medicare reimburses J1950 under Part B at ASP plus 6%, with rates updated quarterly by CMS. Verify the current quarter’s payment file before you bill.

Supported indications are breast cancer, ovarian cancer, endometriosis, uterine fibroids, and central precocious puberty. Prostate cancer is not one of them.

Prostate cancer doses of leuprolide bill under J9217, and Fensolvi bills under J1951. Sending either one out on a J1950 claim invites a denial.

Only two adult strengths bill under J1950: 3.75 mg as 1 unit and 11.25 mg as 3 units. There is no 4-month or 6-month J1950 depot.

Practice management software like Pabau helps practices document medical necessity, track authorization status, and reduce J1950 denials.

HCPCS Code J1950 is the billing code for injection of leuprolide acetate (for depot suspension), per 3.75 mg. It covers the Lupron Depot 3.75 mg and 11.25 mg strengths, plus the Lupron Depot-PED strengths used in pediatric care.

Two related products sit outside this code entirely. Eligard and the prostate cancer strengths of Lupron Depot bill under J9217, and Fensolvi (Tolmar) has its own code, J1951.

Most J1950 denials trace back to three decisions. The strength in the vial sets the code, the total milligrams set the units, and the diagnosis has to sit inside a short approved list. This guide takes them in that order.

Practices running claims management software like Pabau’s can configure leuprolide acetate as a tracked injectable. From there you attach the required ICD-10 codes to treatment records and monitor claim status without manual cross-referencing.

J1950 code details and dosage units

One unit of J1950 equals 3.75 mg of leuprolide acetate. Units are always the total milligrams administered divided by 3.75. Only two adult strengths and four pediatric strengths bill under this code, so any other strength on a J1950 line is a red flag.

Lupron Depot-PED is also supplied in an 11.25 mg three-month presentation, which bills as the same 3 units. Confirm the strength printed on the vial rather than the interval on the order, because two pediatric presentations share the 11.25 mg label.

There is no 15 mg or 22.5 mg adult dose under J1950, and no 4-month or 6-month J1950 depot exists. Those intervals and strengths belong to J9217, which is priced per 7.5 mg.

First Coast Service Options states the rule plainly in LCD L29215. Bill 1 unit for the 3.75 mg monthly injection, or 3 units for the 11.25 mg injection given every three months.

Always confirm the dispensed dose in the chart before calculating units. Billing 1 unit for the 11.25 mg depot is the single most common J1950 coding error.

For OB/GYN practices administering depot injections, building the unit calculation into the encounter template reduces this risk at the point of care. The same milligram arithmetic governs other injectable hormone codes, including J2320.

Covered indications for J1950

J1950 supports oncologic, gynecologic, and pediatric endocrine indications, and prostate cancer is not among them. First Coast Service Options publishes the reference policy in LCD L29215 and its billing and coding article A59160.

That article lists the diagnosis codes that support payment. Other MACs publish their own equivalents, so confirm the list your contractor maintains before you bill.

• Advanced breast cancer: Palliative hormonal treatment in pre-menopausal and peri-menopausal patients. Documentation must confirm the diagnosis and the hormone-responsive treatment intent.
• Ovarian, fallopian tube, and primary peritoneal cancer: Supported through the C56.x, C57.x, and C48.x diagnosis groups. Chart notes should record the histology and the line of therapy.
• Endometriosis: Management of endometriosis pain in pre-menopausal patients when surgical or hormonal alternatives have failed or are contraindicated. Documentation of prior therapy attempts is critical for approval.
• Uterine fibroids (leiomyomata uteri): Pre-surgical reduction of fibroid size, typically limited to six months of therapy. Payers often limit reimbursement to the pre-operative indication specifically.
• Central precocious puberty (CPP): Treatment with Lupron Depot-PED once the diagnosis is confirmed by clinical criteria and laboratory findings. Those findings typically include elevated LH and FSH with advanced bone age. The supported diagnosis code is E22.8, not the more general E30.1.

Prostate cancer (C61) belongs to the J9217 diagnosis group, not this one. CMS billing and coding article A52453 states that J1950 claims billed for prostate cancer are subject to review and possible denial. Androgen deprivation doses of leuprolide therefore bill under J9217, whatever brand the practice stocks.

Off-label uses such as gender-affirming hormone therapy are not supported under the Medicare policy for J1950. Commercial payers may hold separate positions, so verify with each plan before billing.

Digital intake forms built into the clinical workflow capture the indication-specific documentation at the first visit. That beats reconstructing it during a claim dispute.

J1950 ICD-10-CM diagnosis code crosswalk

Every J1950 claim requires a supported ICD-10-CM diagnosis code. The table below lists the code groups that appear in the Medicare billing and coding article for each supported indication. It also shows the one code billers most often attach by mistake.

Always pair J1950 with the most specific ICD-10 code available. A family history or screening code will not support the claim, because the active diagnosis establishes medical necessity. Laterality and site matter on the breast codes, where an entry such as C50.411 replaces an unspecified one.

Some MACs list additional or more granular codes in the article attached to their LCD, so check yours before submission. For practices billing related hormone therapy codes, the IVF CPT codes guide covers adjacent injection coding patterns.

Medicare reimbursement and the ASP fee schedule for J1950

Medicare Part B pays for J1950 using the average sales price (ASP) methodology. The payment amount is ASP plus 6%, calculated quarterly from manufacturer-reported sales data. Because leuprolide acetate pricing moves with market competition and rebate structures, the per-unit rate can shift meaningfully from one quarter to the next.

How Medicare calculates ASP plus 6%

1. Drug manufacturers report average sales prices to CMS quarterly, net of discounts and rebates.
2. CMS publishes the new ASP payment rates approximately 30 days before the quarter begins.
3. The allowed payment is ASP plus 6%, covering both the drug cost and the practice’s acquisition and handling expense.
4. Claims are paid at the lower of the submitted charge or the ASP plus 6% rate for that quarter.
5. The quarterly ASP Drug Pricing File is available directly from CMS drug payment files.

For multi-unit doses, the per-unit ASP rate is multiplied by the number of 3.75 mg units administered. An 11.25 mg depot given in a single session is billed as 3 units at the current quarter’s rate.

Always retrieve that rate from the current quarter’s file rather than relying on prior-year figures. The CMS HCPCS overview explains the full payment methodology for Level II drug codes.

Prior authorization requirements by payer

Medicare does not currently require prior authorization for J1950 at the national level. Prior authorization is standard practice at many commercial payers, including Aetna and Blue Cross Blue Shield plans. Those plans treat GnRH analogs as specialty-tier drugs subject to medical necessity review.

• Aetna: Requires prior authorization for leuprolide acetate under most commercial plans (CPB 0501). Documentation must confirm the supported indication, previous treatment history where required, and current clinical status.
• Blue Cross Blue Shield plans: Requirements vary by regional plan. Many BCBS affiliates require authorization for GnRH agonist therapy beyond the initial course, with re-authorization every six to twelve months.
• Medicare Advantage plans: Requirements differ from traditional Medicare. Always verify with the specific plan rather than the underlying Medicare policy.
• Medicaid: State Medicaid programs set independent requirements. Pediatric CPP cases covered by Medicaid often require specialist attestation and laboratory documentation.

For practices administering leuprolide acetate regularly, build an authorization tracking workflow into the practice management system.

Using automated workflow tools to flag upcoming expiry dates prevents mid-treatment coverage lapses. Those lapses end in denied claims and awkward patient conversations. Record the authorization criteria for each indication in the chart before administration, not after a denial.

Documentation requirements for a clean claim

Medicare policy for leuprolide acetate, including LCD L29215 and billing and coding article A59160, requires specific clinical documentation for J1950 claims. That documentation must exist in the patient’s record at the time of the claim, not retroactively after a request for information.

• Confirmed diagnosis: Pathology, imaging, or laboratory results establishing the supported indication. Examples include a pathology report for hormone-responsive breast or ovarian cancer, pelvic imaging for fibroids, and LH, FSH, and bone age results for CPP.
• Indication-specific medical necessity: For endometriosis, documentation of failed or contraindicated alternative therapies. For the oncologic indications, the histology, hormone receptor status, and line of therapy.
• Prescriber order: Signed order specifying the depot formulation, strength, and frequency. The ordered dose must match the units billed.
• Administration record: Date and place of service, lot number, route of administration, and administering clinician. Medicare Part B drug audits look for all four.
• Frequency limitations: MAC policies specify maximum administration intervals. Billing more frequently than the approved interval without documented clinical justification triggers automatic review.

Practices that use structured clinical records with indication-specific fields are less likely to face documentation deficiencies during audit. Amending a chart after a claim is questioned carries compliance risk. It also rarely overturns a denial based on documentation missing at the time of service.

Billing instructions and claim submission

J1950 is billed on the CMS-1500 claim form for professional billing, or on the UB-04 in an institutional outpatient setting. The fields and rules below reflect standard Medicare Part B billing for office-administered injectable drugs.

NDC reporting is mandatory for Medicaid and increasingly common for commercial payers. Each Lupron Depot and Lupron Depot-PED strength carries its own NDC. Report the number from the vial dispensed rather than a default stored in the drug library.

Drug wastage policy for the JW and JZ modifiers has changed in recent years. Verify current requirements with your AAPC HCPCS code reference and your MAC’s local billing guidance. The J9217 guide covers the same claim fields for the prostate cancer strengths.

Common billing errors and denial reasons

J1950 claims fail in predictable ways, and most of those failures are preventable with a pre-submission checklist. The patterns below come from CMS billing and coding articles, MAC guidance, and payer policies such as Aetna CPB 0501.

• Prostate cancer billed under J1950: C61 is not in this code’s diagnosis group. Androgen deprivation doses belong under J9217, and CMS article A52453 flags the J1950 version for review and possible denial.
• A strength that does not exist under this code: There is no 15 mg or 22.5 mg adult J1950 dose. Those strengths are J9217 territory, and Fensolvi doses belong to J1951.
• Unit miscalculation: Billing 1 unit for the 11.25 mg depot is the most frequent error. Calculate units as total milligrams administered divided by 3.75.
• Missing or unsupported ICD-10 code: Submitting a diagnosis code the applicable policy does not list. A non-specific code also fails where the active diagnosis is required.
• Frequency violations: Administering and billing before the approved interval has elapsed. Some MACs flag claims submitted fewer than 25 days after the prior monthly administration.
• Prior authorization not obtained: Billing commercial payers without securing authorization first. Requirements change annually, so never assume last year’s approval covers the current formulary year.
• NDC mismatch: Reporting the wrong NDC, or omitting it entirely on Medicaid and commercial claims. Always use the NDC from the vial dispensed.
• Place of service error: Billing POS 11 when the drug was administered in an outpatient hospital setting. POS 22 applies there, and different payment rules govern.
• Missing documentation: No prescriber order, no administration record, or no indication-specific medical necessity notes at the time of submission.

In ongoing hormone therapy, one denial repeats itself unless the root cause is fixed before the next administration date. Using prescription management software that links the drug order to the diagnosis and the administration record catches the problem upstream of billing.

The HIPAA compliance guide for medical offices covers the record retention rules that apply to drug billing audits.

J1950 vs related HCPCS codes: Key differences

Leuprolide acetate is billed under more than one HCPCS code, and that is where most J1950 errors begin. The strength in the vial, not the drug name, decides which code applies. The table below shows when each code is correct.

Why prostate cancer doses bill under J9217

J9217 is the general leuprolide acetate depot code priced per 7.5 mg, and it is not specific to Eligard. Both Eligard and the prostate cancer strengths of Lupron Depot bill under it. Its unit math runs 7.5 mg as 1 unit, 22.5 mg as 3 units, 30 mg as 4 units, and 45 mg as 6 units.

Those strengths map to the 1-month, 3-month, 4-month, and 6-month depot intervals in that order. Note that 22.5 mg is the three-month dose under J9217, so it is not a six-month strength on any leuprolide claim. For men’s health practices running androgen deprivation programs, J9217 is the code the claim should carry.

Why Fensolvi bills under J1951

Fensolvi is a brand-name six-month subcutaneous depot from Tolmar, indicated for central precocious puberty. It is not a generic version of Lupron Depot, and it holds its own permanent code, J1951, effective July 1, 2021. J1951 is priced per 0.25 mg, so a single 45 mg dose is reported as 180 units.

Billing Fensolvi as 12 units of J1950 is a unit and product mismatch that payers catch quickly. Pediatric endocrinology practices that stock both products should keep them on separate lines in the drug library. Each line carries its own code.

J9155 (degarelix) sits in a different drug class again. Degarelix is a GnRH antagonist rather than an agonist, and it suppresses testosterone immediately without the initial surge.

Billing J1950 when degarelix was administered, or the reverse, misrepresents the drug given and creates False Claims Act exposure. Check the descriptor against the NLM HCPCS API before the claim goes out.

How Pabau keeps J1950 claims clean before submission

The J1950 checks usually live in three separate places. The strength dispensed sits in the chart, the authorization sits in a payer portal, and the unit conversion sits in the biller’s head. Nobody holds all three at the moment the injection is given, and that moment decides the claim.

Pabau keeps them in one record. You can store each leuprolide product as its own billable item, with the correct code and unit conversion. The 11.25 mg dose then posts as 3 units of J1950, and a prostate cancer dose posts under J9217.

Supported diagnosis codes attach to the treatment record, and authorization dates sit on the patient file where clinical staff can see them.

The result is fewer claims that need rework. Your billers spend their time on exceptions rather than re-checking every vial, and denials stop repeating across a course of therapy.

Reduce J1950 claim denials with Pabau

Pabau’s claims management tools help gynecology, oncology, and pediatric practices track leuprolide authorization status. Attach ICD-10 codes to patient records, and bill the right code for the strength dispensed. See how it works in your practice.

Book a demo

Conclusion

Most of J1950 comes down to a habit at the point of administration. Read the strength off the vial first, and the code, the units, and the diagnosis all follow from it. Practices that build that check into the injection visit stop reworking the same denial every cycle.

The trade-off worth remembering is where the work sits. Two minutes of checking before submission costs less than the weeks a denial takes to unwind. Book a demo to see how Pabau tracks authorization status and posts the right code for the strength dispensed.

Continue your research

Coding an office-administered antibiotic instead? HCPCS code J2010 covers how to report the drug, the units, and the wastage modifiers.

Need the wider Medicare picture? Medicare billing for practices explains claiming channels, payment models, and the compliance rules behind them.

Billing chemotherapy drugs in the same practice? HCPCS code J9267 covers per-milligram unit reporting for an infused oncology drug.

Billing another closely reviewed injectable? HCPCS code J0800 covers corticotropin claims, where payers scrutinize medical necessity just as hard.

Frequently asked questions